From Enterprise Therapeutics Ltd Nov 25 2024 Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in The European Journal of Medicinal Chemistry. The paper describes the medicinal chemistry optimization of a new series of ENaC blockers, resulting in the invention of ETD001, Enterprise's lead asset, a